AI-Generated Summary

This article details recent institutional investor activity in BioMarin Pharmaceutical Inc. (BMRN), noting Fifth Third Bancorp's trimmed position alongside other hedge funds adjusting their holdings. It also provides an overview of recent analyst ratings, which show a consensus 'Moderate Buy' and an average price target for the company.

In a nutshell

This report offers insights into current institutional investor sentiment and market valuation perspectives for BioMarin Pharmaceutical. While no single transaction is market-moving, the collective activity and analyst consensus provide a snapshot of BMRN's standing among financial professionals.

Source: ETF Daily News